z-logo
Premium
Role of AT1 receptors over the oxidative stress in chronic renal failure (CRF)
Author(s) -
Dugaich Adriana Poli Castilho,
Mantovan Nubia Fardin,
Boim Mirian Aparecida,
Ribeiro Daniel Araki,
Campos Ruy Ribeiro,
Bergamaschi Cassia Toledo
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.1059.17
Subject(s) - candesartan , oxidative stress , medicine , endocrinology , tbars , angiotensin ii receptor type 1 , renal function , angiotensin ii , nephrectomy , creatinine , angiotensin receptor , kidney , chemistry , blood pressure , lipid peroxidation
CRF is a progressive condition marked by deteriorating kidney function over time. Elevated blood pressure, renin‐angiotensin system and the imbalance of antioxidant defenses are involved in the progression of renal diseases. The aim of this study was to evaluate the effects of chronic treatment with angiotensin AT 1 receptor blockade (Candesartan) in the oxidative stress and evolution of CRF. Wistar rats were divided in 3 groups: control (C, n=6), CRF (n=6) and CRF + Cand (n=6). CRF was induced by the 5/6 nephrectomy model. Treatment with Cand, 25 mg/Kg VO (2 weeks, daily) started 6 weeks after surgery. Creatinine clearance (CrCl) and TBARS (indicative of oxidative stress) were evaluated. Animals of CRF presented a reduction in CrCl and Cand treatment improves this effect (C 2,1±0,2 x CRF 0,9 ±0,1 x CRF + Cand 1,5±0,2 ml/min). Plasmatic levels of TBARS are raised in CRF and Cand treatment normalized this values (C 2,0±0,2 x CRF 3,6 ±0,06 x CRF +Cand 1,0 ± 0,3 nmoles/ml). These results suggest that blockade of AT 1 receptor reduces oxidative stress and improve renal function in CRF rats. The reduction of oxidative stress can be an important factor against progression of renal disease. Supported by: CNPq

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here